Lobomycosis or lacaziosis is a chronic subcutaneous fungal infection, caused by the fungus Lacazia loboi, which is phylogenetically related to Coccidioides, Blastomyces,
Background
The virologic and histologic outcomes of a hepatitis C virus (HCV)–infected liver graft into an HCV‐negative recipient are not well understood. We aimed to evaluate the sustained virologic response (SVR) rate and the liver histology at 1 year post‐Orthotopic liver transplantation (OLT) with an HCV‐infected graft.
Methods
A total of 33 patients received the HCV antibody (Ab)+/nucleic acid amplification test (NAT)+ graft. Of these patients, 23 were HCV‐negative recipients and 10 were HCV‐positive recipients. The 1‐year biopsy data were available for 24 patients: 15 patients in HCV‐negative group who received an HCV Ab+/NAT+graft and 9 patients in HCV‐positive group who received an HCV Ab+/NAT+ graft. Patients with (+) HCV ribonucleic acid (RNA) were started on direct‐acting antiviral (DAA) treatment approximately 107 days after OLT using either a Glecaprevir‐Pibrentasvir or Sofosbuvir‐Velpatasvir or Sofosbuvir‐Ledipasvir.
Results
All patients (n = 33) were treated with DAA and achieved SVR. The 1‐year post‐OLT liver biopsies were available in 24 patients: 9 patients had F1 and F2 fibrosis and 17 patients had minimal to moderate inflammation. There was no statistical difference in fibrosis and inflammation between the HCV‐negative vs. HCV‐positive recipients. All patients who received the NAT+ graft developed viremia and subsequently achieved SVR with treatment.
Conclusion
At 1 year protocol liver biopsy, patients had inflammation consistent with viral hepatitis despite the successful eradication of HCV.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.